公开(公告)号：US20240156946A1

公开(公告)日：2024-05-16

申请号：US18268736

申请日：2021-12-21

Applicant: CUREVAC SE ,  GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Nicole ROTH ,  Diego Chaves MORENO ,  Hans Wolfgang GROßE ,  Dominik VAHRENHORST ,  Susanne RAUCH

IPC: A61K39/215 ,  C07K14/005

CPC classification number: A61K39/215 ,  C07K14/005 ,  A61K2039/6018

Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

公开(公告)号：US20220331422A1

公开(公告)日：2022-10-20

申请号：US17829004

申请日：2022-05-31

Applicant: CureVac AG ,  GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Nicole ROTH ,  Diego Chaves MORENO ,  Hans Wolfgang GROßE ,  Dominik VAHRENHORST ,  Susanne RAUCH

IPC: A61K39/215 ,  A61K9/127 ,  A61K31/713 ,  C12N15/113 ,  A61K9/51

Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

公开(公告)号：US20220202930A1

公开(公告)日：2022-06-30

申请号：US17558257

申请日：2021-12-21

Applicant: CureVac AG ,  GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Nicole ROTH ,  Diego Chaves MORENO ,  Hans Wolfgang GROSSE ,  Dominik VAHRENHORST ,  Susanne RAUCH

IPC: A61K39/215 ,  A61P31/14 ,  A61K9/127 ,  A61K47/69 ,  A61K47/60 ,  A61K47/26 ,  C12N7/00

Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

公开(公告)号：US20240066114A1

公开(公告)日：2024-02-29

申请号：US18043317

申请日：2021-08-30

Applicant: CureVac SE

Inventor： Susanne RAUCH ,  Nicole ROTH ,  Benjamin PETSCH ,  Wolfgang GROSSE

IPC: A61K39/215 ,  A61K9/127 ,  A61K9/19 ,  A61P31/14

CPC classification number: A61K39/215 ,  A61K9/1272 ,  A61K9/19 ,  A61P31/14 ,  A61K2039/53

Abstract: The present invention is inter alia directed to compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus membrane protein (M), nucleocapsid protein (N), non-structural protein, and/or accessory protein or an immunogenic fragment or immunogenic variant thereof. The composition may additionally comprise at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus spike protein (S). The nucleic acid sequences of the compositions are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The compositions provided herein are for use in treatment or prophylaxis of an infection with at least one Coronavirus, and may therefore be comprised in a vaccine, preferably a multivalent vaccine. The invention is also directed to first and second and further medical uses and to methods of treating or preventing Coronavirus infections.